Biotie Therapies

📍 Turku, Finland👥 5 employees💰 Last funded Jan 2009
Pharmaceutical Manufacturing🌐 biotie.com
Website LinkedIn
Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Bioties development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinsons disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinsons disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a part of Acorda Therapeutics Inc. Group (”Acorda”) and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Biotie Therapies?
Biotie Therapies has 1 investors on record on gritt.io.
When did Biotie Therapies last raise funding?
The most recent investment in Biotie Therapies recorded on gritt.io was in January 2009.
What industry is Biotie Therapies in?
Biotie Therapies operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Biotie Therapies based?
Biotie Therapies is headquartered in Turku, Finland.